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A key issue is the rate of production of homocysteine within various tissues, an index of SAM metabolism, and the fate of this homocysteine through either methylation to methionine (thus completing the methionine cycle), conversion to cysteine, or release into the plasma. In humans, studies in vivo have been restricted to plasma kinetics (1, 24, 37) but without knowing if these reflect common responses across all tissues or are dominated by just a few organs. From more detailed studies in rodents, liver, kidney, and pancreas are considered the main sites of methionine cycle activity, based on measurements in vitro of the enzyme activities of betaine homocysteine methyltransferase (BHMT) and methionine synthase (MS; N-5-methyltetrahydrofolate transferase) (41) , but this does not mean they have the same end points of homocysteine metabolism. For example, it has been suggested that most of the plasma methionine derived from methylation of homocysteine arises from liver with only minor contributions from other tissues (32) , and sophisticated models have been constructed to predict hepatic methionine cycle metabolism (27) . There are differences between tissues, however. For example, while the liver exports homocysteine in vitro (34) the kidney is a net importer in vivo (5) , with most directed toward synthesis of cystathionine (14) . This highlights that plasma hyperhomocysteinemia reflects a combination of intracellular synthesis and export and/or decreased removal by tissues and that calls to rectify "the lack of information as to the mechanism(s) whereby homocysteine is transported from liver to plasma" (25) need to be accompanied by more information on the ability of other tissues to produce, import, and metabolize homocysteine, especially when diets are imbalanced or metabolic priorities are altered.
Some of this information is provided within the current study, which addresses three issues. First, what is the contribution of individual tissues to plasma homocysteine? Second, is tissue release or uptake the predominant mechanism for regulation of plasma homocysteinemia? Third, how is methionine cycle activity within individual tissues and the regulation of homocysteinemia affected by either increased or decreased supply of methyl groups? These objectives were tackled by stable isotope procedures based on isotopomer analysis. The first involved infusion of bis-[1-13 C,methyl-2 H 3 ]methionine (36, 38) , whereas the second utilized [1- 13 C]homocysteine in combination with [U- 13 C]methionine. The study involves virgin female rats to provide basal information before examination of changes in maternal and fetal metabolism during pregnancy in response to dietary imbalances that impact on the methionine cycle.
MATERIALS AND METHODS
Both objectives were tackled by isotopomer-based procedures. The first involved infusion of bis-[1-13 C,methyl-2 H3]methionine (36, 37) , whereas the second utilized [1- 13 C]homocysteine in combination with [U- 13 C]methionine. The synthesis of [1-13 C]homocysteine is described in the APPENDIX.
Animals and Diets
All rodent studies were approved by the Ethical Review Committee of the Rowett Institute of Nutrition and Health and conducted in accordance with the conditions of the United Kingdom Animal Scientific Procedures Act (1986).
The diets (Table 1) were formulated in accordance with AIN-93 regulations (30) as described previously (20, 28) . Diets contained the equivalent of 18% protein, provided as 9% casein and a supplement of crystalline amino acids (Spodefell, London, UK) in similar amounts to those present in the 9% casein. Methionine was omitted from the supplement to allow subsequent diet manipulation. Similarly, the vitamin mix was prepared devoid of folate, and this was added as a supplement where appropriate. Dietary treatments allowed a 2 ϫ 2 factorial design (experiment 1) with either excess (ϩM) or adequate (ϪM) methionine (5.6 and 2.3 g/kg total diet, respectively) and with adequate folate (0.2 g/kg diet) plus choline (2 g/kg diet) either present (ϩFC) or absent (ϪFC). To prevent sulfur group deficiency, cysteine was supplemented at 20.2 g/kg diet.
Experiment 1
Virgin female group-housed Hooded-Lister (Rowett strain) rats (7.5 wk of age, start body weight 168.2 Ϯ 2.1 g; n ϭ 24) were separated into four equal weight-matched groups. Animals were fed ad libitum for 5 wk one of the four experimental diets (Table 1) .
Experiment 2
Virgin female group-housed Hooded-Lister rats (8.5 wk of age, start body weight 182.5 Ϯ 2.0 g, n ϭ 16) were divided into two equal weight-matched groups and offered one of the low-methionine diets detailed above (see Table 1 ) with either adequate (ϪMϩFC) or devoid (ϪMϪFC) of folate plus choline. These diets were identical to those for experiment 1 except for the addition of cysteine at 3.9 g/kg diet.
Infusion Procedures
In pilot studies, groups of six rats fed the study diets with either normal or no folate and choline present for the previous 4 wk were given primed infusions of either [1- 13 C,methyl-2 H3]methionine or [U- 13 C]methionine and [1-13 C]homocysteine, and blood samples were taken at intervals up to 6 h from the caudal vein. Pseudo-plateau enrichments were attained in plasma within 3-4 h for both the labeled forms of methionine and homocysteine infused and also these produced as secondary products within tissues and exported to plasma [e.g., [U- 13 C]homocysteine and [1-13 C]methionine (data not shown)]. Attainment of plateau for these secondary metabolites was taken to indicate that isotopic plateau had been achieved within the tissues where these were formed originally.
For experiment 1, after 5 wk on diet, the rats were trained to a commercial restraint tube (Harvard Apparatus, Kent, UK) and then infused via a tail vein for 4 h with [1-13 C,methyl-2 H3]methionine (2.0 mg/ml saline, flow rate 0.36 ml/h; Mass Trace, Woburn, MA), following an initial priming dose infused over 8 min, equivalent to 1 h of infusion. Infusions were by syringe pumps (Scientific and Research Instruments, Edenbridge, Kent, UK). At the end of the infusion, the rats were killed by stunning and cervical dislocation followed by decapitation, and the trunk blood obtained was collected into heparinized tubes on ice. The liver, pancreas, heart, lung, kidney, small intestine, spleen, reproductive organs, muscle, skin, and brain were removed in sequence quickly (Ͻ5 min), washed in ice-cold 0.15 M NaCl, and immediately frozen in liquid N. Samples were then stored at Ϫ80°C until analysis.
Procedures for experiment 2 were similar to those for experiment 1 except that the infusate comprised [U-
13 C]methionine (1.5 mg/ml saline; flow rate 0.36 ml/h; Cambridge Isotope Laboratories, Andover, MA) plus [1- 13 C]homocysteine (0.2 mg/ml saline for animals on diet ϪMϩFC and 0.4 mg/ml saline for animals on diet ϪMϪFC), and the infusion period was increased to 5 h. At slaughter, midcolon was added to the list of tissues removed.
All methods for analysis of metabolite concentrations in plasma and determination of enrichments in plasma and tissue homogenates are detailed in the APPENDIX. 
Theoretical Background
For experiment 1, the [1-13 C,methyl-2 H3]methionine (m ϩ 4 methionine) infused into the blood is extracted by tissues and either used for protein synthesis or converted to [1- 13 C]homocysteine (m ϩ 1 homocysteine), with the loss of the labeled methyl group. Transfer of a methyl group from either 5-methyltetrahydrofolate or betaine to [1- 13 C]homocysteine yields [1-13 C]methionine (m ϩ 1 methionine). Alternatively the homocysteine can be converted to cysteine and 2-oxo- [1- 13 C]butyrate (not measured). The ratio of m ϩ 1 to m ϩ 4 methionine in a tissue compared with plasma gives a relative measure of synthesis from homocysteine. Comparison of enrichments of methionine and homocysteine in plasma and tissues allows the relative flows from plasma, protein breakdown (assumed equal to protein synthesis), and methylation of homocysteine to be estimated by a mathematical model (see APPENDIX) based on the structure shown in Fig. 2 .
For experiment 2, where the rats were infused with [U- 13 C]methionine (m ϩ 5 methionine), this is extracted by the plasma and may be converted to m ϩ 4 homocysteine with subsequent fates as export to plasma, conversion to cysteine and 2-oxo-[U- 13 C]butyrate (not measured), or methylation to produce m ϩ 4 methionine. The enrichments of these various products give similar information to that obtained in experiment 1 with, other than the m ϩ 5 methionine, all the labeled metabolites generated within the tissues. The [1- 13 C]homocysteine infused into plasma may enter the cell and be diluted by homocysteine produced by intracellular demethylation of methionine, and this may then be converted to [1- 13 C]methionine. Together the isotopomers of m ϩ 1 and m ϩ 4 homocysteine within a tissue allow estimation of the relative contribution from the two sources, import from plasma and synthesis from methionine. Similarly, isotopomer analysis of m ϩ 0, m ϩ 1, m ϩ 4, and m ϩ 5 methionine allows the intracellular inflows from plasma, methylation of homocysteine, and release from protein breakdown to be determined. The contributions of tissue-derived homocysteine and methionine to plasma concentrations can also be obtained from the relative enrichments of the isotopomers from those infused in the primary pool (m ϩ 1 homocysteine and m ϩ 5 methionine) and those produced in tissues and then exported (m ϩ 1 and m ϩ 4 methionine and m ϩ 4 homocysteine). In addition, the irreversible loss of whole body homocysteine rate could also be determined.
The various enrichments obtained in both experiments were then used to estimate metabolite flows with the mathematical model described in the APPENDIX.
Statistics
Experiment 1 (diets ϪMϪFC, ϪMϩFC, ϩMϪFC, ϩMϩFC, n ϭ 8/diet). Technical problems were encountered with three of the infusion procedures in experiment 1; hence, no kinetic data were obtained for one rat fed ϩMϩFC and two offered ϪMϪFC. Consequently, the groups were unbalanced and were analyzed by residual maximum likelihood (REML) procedures. For comparison between tissues, animal was considered as a random effect, with tissue, diet, and their interaction as fixed effects. Because the tissue by diet interaction was significant (P Ͻ 0.05), the effect of diet within each tissue was then analyzed by REML with fixed effects for dietary methionine (ϪM, ϩM), dietary folate and choline (ϪFC, ϩFC), and their interaction. Where any principal effects showed a significant effect at the 5% level, means were compared with post hoc t-test at the 1% significance level.
Experiment 2 (diets ϪMϪFC, ϪMϩFC, n ϭ 8/diet). For comparison between tissues, data were analyzed by ANOVA with animal as a random effect while tissue, diet, and their interaction were regarded as fixed effects. Because the interaction was significant (P Ͻ 0.05), data within each tissue were then analyzed by two-sample t-test to test for differences between the two diets (ϪFC, ϩFC).
Data were analyzed using Genstat 10th edition (VSN International, Hemel Hempstead, UK). All individual means in the text are presented Ϯ SE while, for comparisons between treatments in the tables, the SED are given.
RESULTS

Experiment 1: Effect of Dietary Methionine and Folate Plus Choline on Whole Body and Tissue Methionine Kinetics
General effects and tissue responses. Neither the level of methionine supplementation nor the presence or absence of dietary folate plus choline affected body weight gain (average 60.0 Ϯ 8.3 g/5 wk). No adverse health effects were noted.
For clarity, data are first compared for all treatments combined to show general effects and differences between tissues. As expected, following infusion of the bis-labeled methionine (m ϩ 4), all tissues showed a lower intracellular tracee-totracer ratio (TTR) of m ϩ 4 methionine than plasma because of dilution by unlabeled methionine released from protein breakdown (data not shown). The intracellular TTR of m ϩ 1 methionine produced by methylation of homocysteine was lower than plasma for all tissues (P Ͻ 0.01; Fig. 3 ) except pancreas (P Ͻ 0.001), which was higher. Homocysteine concentrations obtained by the gas chromatography-mass spectrometry procedure varied markedly between tissues. The largest concentrations were recorded for lung, spleen, muscle, and skin, with m ϩ 1 homocysteine TTR in the lung, indicative of demethylation of m ϩ 4 methionine, not different from plasma while the other three were lower (P Ͻ 0.01; Fig. 4 ). Moderate concentrations, at the limit of confident quantification of TTR, were obtained for liver, small intestine, and pancreas, with the TTR for liver and small intestine lower than plasma (P Ͻ 0.01) while the values for pancreas were greater (P Ͻ 0.001). For the other tissues, the homocysteine concentrations were too low to give reliable estimates.
If the ratio of intracellular m ϩ 1 to m ϩ 4 methionine TTR exceeds that in plasma, then intracellular synthesis of methionine has occurred, as was the case for most tissues (Table 2) . Across diets, the greatest increase in ratio was observed for liver followed by pancreas (both P Ͻ 0.001 compared with the ratio in plasma). Other tissues also converted homocysteine to methionine, but to a lesser extent (all P Ͻ 0.01), except for brain, where the ratio was similar to plasma.
The contribution of plasma inflow to total tissue methionine flux (inflow ϩ methylation ϩ protein degradation) differed between groups of tissues (P Ͻ 0.01) and ranged from 0.24 to 0.30 (kidney, liver, small intestine), 0.37 to 0.45 (brain, skin, spleen, reproductive organs), 0.56 to 0.59 (heart, lungs), and 0.69 to 0.75 (muscle and pancreas). The contribution of homocysteine methylation to tissue methionine flux was lower in all tissues and ranged from 0.13, for both liver and pancreas (P Ͻ 0.001, compared with all other tissues), to Ͻ0.02 for skin.
Effect of methionine and folate plus choline supply. Folate concentrations were reduced in plasma (56.0 Ϯ 4.6 vs. 14 Ϯ 1.2 ng/ml, P Ͻ 0.001) and liver (37.4 Ϯ 3.0 vs. 9.9 Ϯ 0.8 g/g wet wt, P Ͻ 0.001) during dietary folate plus choline deficiency but were unaffected by dietary methionine level. Plasma methionine concentrations were not altered by either the reduced dietary methionine supply (52.9 Ϯ 1.2 vs. 54.9 Ϯ 1.4 nmol/g, P Ͼ 0.10) nor by the removal of folate plus choline (52.6 Ϯ 1.1 vs. 55.3 Ϯ 1.4 nmol/g, P Ͼ 0.10). Similarly, total plasma free cysteine was unaffected by diet and averaged 224 nmol/g. Total homocysteine concentrations in plasma were not altered by dietary methionine content (13.2 Ϯ 2.9 vs. 18.0 Ϯ 4.4 nmol/g, P Ͼ 0.10) but were increased from 5.1 Ϯ 0.2 to 26.0 Ϯ 3.0 nmol/g (P Ͻ 0.001) when folate plus choline were omitted.
Whole body irreversible loss rate (ILR) increased at the lower methionine intake, both when the TTR of either m ϩ 4 methionine (36.7 Ϯ 2.0 vs. 29.3 Ϯ 0.9 mol/h, P ϭ 0.002) or m ϩ 1 homocysteine (48.3 Ϯ 2.0 vs. 43.2 Ϯ 0.6 mol/h, P ϭ 0.02) in the plasma was used as precursor. In neither case did the amount of folate plus choline in the diet affect the ILR. Across all dietary treatments, the ratio of plasma m ϩ 1 homocysteine to m ϩ 4 methionine was 0.713 Ϯ 0.019 (P Ͻ 0.001 different from unity) but was greater for the ϪMϩFC diet (0.834, P Ͻ 0.05) compared with the other diets (average 0.673).
Both methionine and folate plus choline impacted on the ratio of m ϩ 1 to m ϩ 4 methionine in plasma (Table 2) , an index of intracellular conversion of homocysteine to methionine that is exported to plasma. This ratio decreased in the absence of dietary folate plus choline (P Ͻ 0.001) but increased with the lower methionine supply (P ϭ 0.01), particularly for animals fed the ϪMϩFC diet (MϫFC, P Ͻ 0.01). These plasma data reflect changes in response to diet at the tissue level (Table 2 ). For example, lower dietary methionine increased the ratio of m ϩ 1 to m ϩ 4 methionine in the heart (P Ͻ 0.01), small intestine (P Ͻ 0.01), spleen (P ϭ 0.001), and pancreas (P Ͻ 0.05). In contrast, the omission of folate and choline from the diet decreased the ratio of m ϩ 1 to m ϩ 4 methionine in liver (P Ͻ 0.001), muscle (P Ͻ 0.01), and pancreas (P Ͻ 0.05), with the effect in liver and muscle greater at the lower methionine intake (M ϫ FC, P Ͻ 0.05). Low folate plus choline increased the ratio in heart, however (P Ͻ 0.05).
Experiment 2: Effects of Dietary Folate Plus Choline on Whole Body and Tissue Homocysteine Metabolism
Whole body metabolism. Body weight gain over the duration of the experiment was similar between the two diet groups and averaged 44.9 Ϯ 3.1 g over the 5 wk. Whole body ILR of methionine (protein synthesis plus demethylation) averaged 47.1 Ϯ 1.1 mol/h, based on the harmonic mean of tissue (20) , small intestine (SI; 18), and liver (15) . Hatched bars are for tissues where the areas for homocysteine by gas chromatography-mass spectrometry (GC-MS) are at the limit of confident detection. Different letters denote differences (P Ͻ 0.01) between tissues and/or plasma based on REML analysis with animal as a random effect and diet, tissue, and their interaction as fixed effects. (20) . Different letters denote differences (P Ͻ 0.01) between tissues and/or plasma based on residual maximum liklihood (REML) analysis with animal as a random effect and diet, tissue, and their interaction as fixed effects. RO, reproductive organs; SI, small intestine. enrichments of free m ϩ 5 methionine and was not altered by diet (P Ͼ 0.10). Lower values were obtained if either plasma m ϩ 5 methionine or m ϩ 4 homocysteine was used as the precursor pool (23.3 Ϯ 0.6 and 26.4 Ϯ 0.6 mol/h, respectively), again with no effect of diet (P Ͼ 0.10). As with experiment 1, the ratio of plasma TTR for synthesized original methionine (i.e., m ϩ 4 to m ϩ 5) was decreased (0.221 Ϯ 0.008 vs. 0.257 Ϯ 0.008, P Ͻ 0.01) when the diet was deficient in folate plus choline. Demethylation in both absolute terms (5.5 Ϯ 0.19 vs. 9.0 Ϯ 0.53 mol/h, P Ͻ 0.001) and as a fraction of total methionine ILR (0.118 Ϯ 0.006 vs. 0.190 Ϯ 0.007, P ϭ 0.001) increased when folate plus choline were absent from the diet. In contrast, resynthesis of methionine was not changed (P Ͼ 0.10) by diet manipulation, either in absolute terms (9.6 Ϯ 0.5 mol/h) or as a fraction of ILR (0.203 Ϯ 0.006). These differential responses in methionine demethylation and methylation were reflected in an increased [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]homocysteine ILR (1.3 Ϯ 0.04 vs. 2.8 Ϯ 0.33 mol/h, P ϭ 0.001) when folate and choline were omitted from the diet.
Tissue responses. The TTR of m ϩ 4 homocysteine (Fig. 5) , formed by demethylation of [U- 13 C]methionine, was highest in the pancreas and exceeded that of plasma (P Ͻ 0.001), similar to the observations in experiment 1. Enrichments in the small intestine, skin, and spleen (all P Ͻ 0.001) plus colon (P Ͻ 0.01) were also greater than plasma as was lung (P Ͻ 0.05). Muscle, liver, and heart TTR values were not different from plasma, whereas kidney and brain were lower (both P Ͻ 0.001).
The TTR of synthesized methionine, in both m ϩ 4 and m ϩ 1 forms, was higher in the pancreas (21 and 7%, respectively, both P Ͻ 0.001) than plasma (Fig. 6, A and B) . Interestingly, the enrichment of m ϩ 1 methionine in the heart was even higher than in the pancreas (P ϭ 0.001; Fig. 6B ), indicative of substantial import and methylation of [1- 13 C]homocysteine from plasma. The higher ratio of m ϩ 4 to m ϩ 5 methionine TTR in tissues compared with plasma ( Fig. 7A) indicated that most organs converted homocysteine to methionine. As observed in experiment 1, the liver was the most active site, followed by kidney, brain, pancreas, and spleen (Fig. 7A) . These latter tissues were more active than liver in utilizing homocysteine imported from blood, as indicated by the high intracellular ratios found for m ϩ 1 methionine to m ϩ 1 homocysteine compared with plasma (Fig. 7B) .
The model developed (see APPENDIX) allowed estimation of both relative (methionine and homocysteine) and absolute (methionine only) tissues fluxes. For most tissues, diet had no effect on the fractional synthesis rate (%/day), and combined values were used for the model (heart, 12.5; liver, 74.7; lung, 25.1; midcolon, 51.9; muscle, 4.6; pancreas, 162.4; small intestine, 149.4; skin, 14.9; and spleen, 49.5), except for kidney where values were greater when folate and choline were absent from the diet (78.4 vs. 70.1%/day, P ϭ 0.044). These data were used to estimate the fractional inflows to the intracellaular methionine pool from plasma and methylation of homocysteine (Table 3 ). The total methionine fluxes (mol⅐h Ϫ1 ⅐g Ϫ1 tissue) are also presented, and, from these two sets of data, absolute (14) . Different letters denote differences (P Ͻ 0.01) between tissues and/or plasma obtained by ANOVA with animal as a random effect and diet, tissue, and their interaction as fixed effects.
flows (per g tissue) also can be calculated. In liver, methylation of homocysteine and methionine inflow from plasma were approximately equal and, together, represented Ͼ40% of hepatic methionine flux. For the other tissues, the methionine inflow from plasma exceeded considerably that derived from methylation of homocysteine (Table 3) .
Intracellular homocysteine is derived from two sources, plasma entry and demethylation of methionine. The proportion that arose from plasma entry was Ͻ10% for liver and brain (Table 4 ) compared with skin (89%), heart (68%), and small intestine (38%). Values for muscle, kidney, lung, and pancreas were intermediate and ranged from 17 to 24% (see Table 4 ; for all tissues, the proportion that arose through demethylation can be obtained by difference).
Effect of dietary folate and choline. The mean plasma concentrations of methionine (77.4 Ϯ 1.4 nmol/g) and total cysteine (222 Ϯ 2.6 nmol/g) were not altered (P Ͼ 0.10) by diet, with the latter values similar to those observed in experiment 1 where larger amounts of dietary cysteine were provided. The diet deficient in folate and choline resulted in increased total homocysteine in plasma (from 5.7 Ϯ 0.07 to 14.0 Ϯ 1.17 nmol/g, P Ͻ 0.001). Such diets also reduced the proportion of tissue methionine flux derived from methylation of homocysteine (Table 3) in the liver (P Ͻ 0.01), whereas, in contrast, there were small increases (P Ͻ 0.05) in the proportion for the lung, skin, midcolon, and heart. In the absence of dietary folate and choline, the relative inflow of homocysteine from plasma into liver, pancreas, kidney, midcolon, heart, and muscle increased (P Ͻ 0.01; Table 4 ), whereas there were corresponding decreases for the inflows from demethylation. Tissue homocysteine fluxes were not determined directly, but minimum estimates can be derived from the amount of methionine derived from homocysteine (from Table 4) . By this approach then, per unit tissue weight, pancreas had the greatest conversion of plasma- (14) . Different letters denote differences (P Ͻ 0.01) between tissues and/or plasma obtained by ANOVA with animal as a random effect and diet, tissue, and their interaction as fixed effects. 13 C]homocysteine (B). All data are combined, irrespective of dietary group, and presented as means Ϯ SE. Sample numbers are 16 for each tissue except for skin (14) . Different letters denote differences (P Ͻ 0.01) between tissues and/or plasma obtained by ANOVA with animal as a random effect and diet, tissue, and their interaction as fixed effects. derived homocysteine to methionine (13.7 mol⅐g Ϫ1 ⅐h
Ϫ1
) followed by small intestine (2.6 mol⅐g Ϫ1 ⅐h
), liver and kidney (average 1.4 mol⅐g Ϫ1 ⅐h
), and then heart, spleen, and lung (average 0.9 mol⅐g Ϫ1 ⅐h
).
DISCUSSION
Despite the accepted importance of the methionine cycle for the transfer of methyl groups for a variety of key metabolic reactions (21, 39) and the relationship between plasma homocysteine, a cycle intermediate, and aspects of cardiovascular risk (2, 6, 13), relatively few data are available on the dynamic relationships between tissues in both the production and utilization of methionine cycle metabolites. The current study used isotopomer analysis of labeled forms of both methionine and homocysteine to unravel some of the interactions between tissues and how these are altered by either excess or deficient methyl group provision.
Source of Plasma Homocysteine
The liver is considered a major site of methionine cycle activity, based on the high activities of both MS and BHMT in the liver (12, 21, 41) . Indeed, this is confirmed by the current dynamic data where the fraction of intracellular methionine flux derived from methylation of homocysteine was much greater for liver than any other tissue. The liver has also been assumed to play a major role in regulation of plasma homocysteinemia (25, 35) . Support for this concept arises from observations that release of homocysteine from hepatocytes in vitro is sensitive to methylation demand, including production of serine, creatine, guanidinoacetate, and phosphatidylcholine (26, 35, 34, 40) . Indeed, the rates observed in vitro (1.29 -2.17 nmol⅐mg dry wt Ϫ1 ⅐h
Ϫ1
) (34) , if extrapolated to the liver in vivo (4% body weight) (29) , would more than accommodate (2.0 -3.3 mol/h) the plasma homocysteine flux of 1.3 mol/h found for rats fed the complete diets in the current study.
Nonetheless, other data within the present study do not support a dominant role for the liver as the source of plasma homocysteine. First, much of the homocysteine generated within the liver appears to be methylated to reform methionine. Second, the enrichment of homocysteine derived from demethylation of methionine within the liver was less than that observed in plasma. Indeed, this difference would be amplified further if allowance had been made for the blood present in the liver sample. Therefore, other tissues with intracellular homocysteine enrichments greater than in plasma, namely pancreas, small intestine, and spleen, probably also contribute to the homocysteinemia. The highest intracellular enrichment for homocysteine was observed for pancreas, a tissue that requires methyl groups for both the packaging and release of digestive enzymes, such as amylase (3), and to support the considerable glycine methyltransferase activity for synthesis of sarcosine (31) . The demand of these various mechanisms in the pancreas may account for both the large intracellular folate stores, second only to those in liver (4) , and the high rate of methio- The third origin of intracellular methionine is protein breakdown (PB), and this was assumed to be similar to protein synthesis. The contribution of PB to flow through the intracellular methionine pool is 1 Ϫ (fp ϩ fh), and this was not significantly different (P Ͼ 0.10) between the dietary treatments for any tissue. For each tissue, data were analyzed by two-sample t-test. Flux was not determined for brain. *Flux (mol ⅐ g wet tissue Ϫ1 ⅐ h
) through the tissue intracellular methionine pool was calculated assuming that PB is equal to the rate of protein synthesis (mol ⅐ h Ϫ1 ⅐ g wet tissue Ϫ1 , calculated as described in the APPENDIX), which was then divided by 1 Ϫ (fp ϩ fh).
nine cycle activity observed in the current study. The pancreas, along with liver, was also sensitive to folate and choline deficiency with less of intracellular homocysteine methylated, and this may then be exported and contribute to the elevated plasma homocysteinemia.
Regulation of Homocysteinemia
Plasma homocysteinemia represents the balance between tissue export and import, and these two processes may respond differently between individual organs to challenges (7), including the folate and choline deficiency induced in the present study. In these young female rats, plasma homocysteine enrichment achieved plateau within 3 h of a primed infusion, compatible with rate constants of 1.5-1.7/h, a half-life of Ͻ30 min estimated from the observed ILR, and an assumed homocysteine content in total body water based on plasma concentration. A similar rapid equilibration (3 h) was observed in some human studies (38) but not others (19) .
In response to the deficiency in folate and choline, plasma homocysteine concentrations increased by two-to fivefold, whereas ILR doubled. The latter represents a greater flow through the plasma of homocysteine from tissues, and this greater export may or may not be linked to additional intracellular homocysteine synthesis. The experimental design did not allow intracellular demethylation to be determined directly, although the insensitivity of tissue methionine fluxes to folate and choline deficiency might suggest that any effect on homocysteine synthesis was limited. A more probable cause of the increased ILR was a change in the proportion of homocysteine exported from cells. Indeed, only a small fraction of homocysteine produced within cells is normally exported to plasma. For example, based on the assumption that most of the dietary methionine intake (50 mg/day) was catabolized via the transsulfuration pathway, with homocysteine as an intermediate, this would only represent Ͻ12% of the plasma ILR of homocysteine. Therefore, under control dietary conditions, the majority of homocysteine in the cell is either methylated to methionine or converted to cystathionine. When one of these pathways is inhibited, as when dietary folate and choline are deficient, then a greater fraction of intracellular homocysteine may be released into the blood.
Hyperhomocysteinemia would also occur if there was a reduced removal from the plasma. This is not the reason in the current study, however, because, under conditions of isotope equilibrium, entry and exit through a pool will be equal, so that the higher plasma ILR observed also reflects increased removal. This is supported by the observation that, for many tissues, the proportion of intracellular homocysteine derived from plasma import increased with diets devoid of folate and choline. For tissues such as liver, pancreas, heart, and muscle, where uptake from plasma increased but methylation to methionine decreased and then increased, flow through the trans-sulfuration pathway must have occurred, although this was insufficient to restore plasma homocysteinemia to control values.
As might be expected, tissues with high methionine cycle activity, such as liver and pancreas, showed a relatively low contribution of inward transport (7 and 17%, respectively) to intracellular homocysteine. In contrast, for skin, almost all intracellular homocysteine was derived from inward transport; therefore, little of the cysteine needed to support hair growth came from intracellular methionine (42) . Interestingly, Ͼ50% of homocysteine flux within heart tissue was through entry from the plasma, and this may link to the impaired endotheliumdependent vasodilation (10) observed in other tissues of the cardiovascular system. In addition, the fractional inflow from plasma into kidney increased (from 0.19 to 0.28) with folate and choline deficiency, compatible with the role this organ plays in terms of net removal of homocysteine in vivo (5, 15) accompanied by conversion to cystathionine rather than methionine (14) .
Impact of Dietary Methionine and Synthesis De Novo
The respective rates of demethylation of methionine and methylation of homocysteine reflect the physiological and metabolic demand for methyl groups and the adequacy, or otherwise, of required cofactors. The current data confirm earlier observations (11, 31) that dietary methionine provides a source of methyl groups that can reduce the need for C-1 transfers via folate and betaine to methylate homocysteine. This effect was particularly noticeable for heart, pancreas, small intestine, and spleen but whether this is due to a greater sensitivity to methionine supply per se or the interaction with either folate and/or choline supply is unclear. Furthermore, in the present study, no attempt was made to resolve the separate impacts of folate and choline, but previous observations (32) have shown that deficiency of the former leads to greater export of homocysteine to the plasma but with little effect on the synthesis of methionine, whereas diets devoid of choline have a smaller impact on homocysteine export but inhibit synthesis of methionine. Originally, it was proposed that methionine synthesized within the liver was exported but retained when produced in other tissues (32) , but the current data indicate that the reverse is true, with little of the synthesized methionine that appears in plasma actually of hepatic origin. This is compatible with data from other species where methionine transfers across the liver are dominated by inward, rather than outward, transport (17) . Rather, in the current study, at least 25-50% of synthesized methionine that appeared in the plasma originated from the pancreas.
The mass isotopomer analysis of both synthesized methionine and homocysteine that appears in plasma has implications for isotope kinetic studies. Both have been used as surrogate measures of intracellular methionine enrichments (18, 19, 37, 38) . The current findings indicate that tissues such as liver and pancreas may make a disproportionately large contribution to plasma enrichments of homocysteine compared with other tissues, whereas plasma-based estimates of methionine derived from methylation of homocysteine will underestimate the impact of hepatic metabolism on whole body kinetics. This potential problem is further exacerbated when the differential effects on tissue metabolism of dietary excess and deficiency as observed in the current study are also considered.
Conclusions
The isotopomer approach adopted in the current study confirms the dynamic nature of the methionine cycle in vivo, particularly in the liver. Nonetheless, hepatic sources are not the dominant origin of either homocysteine or synthesized methionine present in the plasma. Other tissues, including the pancreas, make important contributions in young female rats.
Only a small fraction of homocysteine produced within cells is exported to the plasma, and increased plasma homocysteinemia, as induced by dietary folate and choline deficiency, probably reflects increased efflux from tissues rather than increased synthesis. Although removal of homocysteine from the plasma is also increased at the same time, this is insufficient to maintain concentrations at control values. A considerable proportion of intracellular homocysteine is imported from plasma in tissues such as kidney, skin, and heart, and this may reflect different metabolic outcomes, including production of cystathionine and regulation of cardiovascular function. Tissues also varied in the responses to reduced folate and choline provision, and this may have implication for both whole body regulation of methyl group supply and metabolism within specific organs. Such metabolic responses may be magnified under conditions of increased demand for methyl group transfers, such as occurs in pregnancy and where improved C-1 metabolism is widely believed to underlie the reduction in the occurrence of neural tube defects following folate supplementation of foods (16) .
APPENDIX
Synthesis of Homocysteine
The L-[1- 13 C]methionine (1.25 mmol) was dissolved in concentrated HCl (2.5 ml) at room temperature. Dichloroacetic acid (5 mmol) was added, and the mixture was heated under reflux for 12 h at 150°C. The HCl was removed in vacuo at 60°C, and the residue was suspended in ice-cold absolute ethanol. After standing overnight at 4°C, precipitated (4S)-TDC ⅐ HCl (yield ϳ60%, Ͼ97% diastereomeric excess) was filtered and washed with absolute ethanol and tetrahydrofuran. To a suspension of (4S)-TDC ⅐ HCl (0.034 g) in absolute ethanol (3.7 ml, TDC ⅐ HCl-to-ethanol ratio 1:25) containing the pH indicator bromothymol blue, triethylamine was then added dropwise until solution pH rose to ϳ7 and the (4S)-TDC ⅐ HCl was completely dissolved. The solution was heated under reflux at 120°C. Once refluxing was established, 0.3 ml of 0.15 mmol/l ethanolic hydroxylamine hydrochloride was added as five aliquots of 0.06 cm 3 , at intervals of 10 min. Immediately after each addition, the solution was maintained at pH 7-8 with triethylamine. Refluxing was maintained for 1 h after the final addition. The precipitated L-[1-
13 C]homocysteine (yield ϳ80%, Ͼ99% isomeric excess) was collected by filtration, washed thoroughly with ethanol, checked for absence of triethylamine, and air-dried before storage at Ϫ40°C. Mass spectrometry analysis by the chiral column indicated that the product contained only the L-isomer while melting point and nuclear magnetic resonance spectra proved the purity of the product. 13 C]homocysteine for tissue supernatant. These samples were then processed according to the methods detailed below for experiments 1 and 2 and analyzed as described previously (8) . Plasma folate, phosphocholine, choline, and triglyceride concentrations were analyzed as previously described (20, 23) .
Analysis of Plasma and Tissues Concentrations
Analysis of Plasma and Tissue Enrichments by GC-MS
All reagents were obtained from Sigma Aldrich (Poole Dorset, UK), Fisher Scientific (Loughborough, Leicestershire, UK), or VWR International (Lutterworth, Leicestershire, UK).
For experiment 1, tissues (0.5 g) were homogenized by Ultra Turrax (IKA-Werke, Staufen, Germany) in 1.5 ml of ice-cold water containing 10 mM dithiothreitol (DTT). Samples were left on ice for 20 min and then 0.5 ml of 35% (wt/vol) 5-sulfosalicylic acid dihydrate (SSA) was added and mixed, and samples were centrifuged for 15 min at 700 g at 4°C. The supernatants were then centrifuged for a further 5 min at 9,500 g until clear. Supernatants were stored at Ϫ80°C until derivatization and analysis.
Plasma samples (100 l) were thawed on ice, and 50 l of 100 mM DTT were added, vortex mixed, and incubated at room temperature for 20 min. This was to release cysteine and homocysteine from protein and dimer complexes. Samples were deproteinized by addition of 70 l 35% (wt/vol) SSA, vortex mixed, and centrifuged at 9,500 g for 5 min at room temperature.
Approximately 100 l of the supernatant from a plasma or tissue sample were applied to 13 mm of Dowex 50Wϫ8 resin (50 -100 mesh, H ϩ form) in a 1-ml disposable pipette tip packed with 2 mm cotton wool. The resin was then washed with 2 ϫ 1.2 ml water, and the sample was eluted with 0.5 ml of 2 M NH4OH. This eluate was then dried under a gentle stream of nitrogen at 85°C, dissolved in 10 l 100 mM DTT plus 50 l of 2 M NH4OH, and incubated at room temperature for 30 min. This converts homocystine and cystine to their respective monomers. Samples were dried under nitrogen at 85°C and the tert-butyldimethylsilyl (tBDMS) derivatives were formed by heating in 60 l N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide-acetonitrile Procedures were modified for experiment 2. For preparation of tissues, the low amounts of homocysteine present necessitated techniques that improved GC-MS sensitivity and to prevent enzyme reactions occurring during the preparation stage. The procedures were similar to experiment 1 except that the homogenized tissue samples (0.5 g) were left on ice for 20 min before addition of the 0.5 ml 35% (wt/vol) SSA. The pellet was retained for protein-bound enrichment, whereas the supernatant was put through a desalting procedure where 4 mm of AG 50W-X8 resin (mesh size 100 -200, H ϩ form) was placed in the modified pipette tip, and this was washed with 2 ϫ 1 ml water, and the sample was eluted with 0.4 ml of 2 M NH4OH4 into a v-vial containing 10 l 100 mM DTT and derivatized immediately (see below). The protein pellet was thoroughly washed four times with 7% SSA (3 ml on each occasion), and then the equivalent of ϳ20 mg of protein were hydrolyzed in sealed tubes in 6 M hydrochloric acid at 105°C for 18 h in the presence of 5 mM DTT. The protein-bound methionine enrichment was then determined as the tBDMS derivative. For the preparation of plasma, to 100 l of plasma, 20 l of 100 mM DTT was added, mixed, and incubated at 4°C for 20 min. Samples were deproteinized with 100 l 15% (wt/vol) SSA and centrifuged at 9,500 g for 5 min. The supernatant was then desalted and treated as detailed for tissues.
Both the plasma and tissue sample extracts in the alkaline DTT eluate were incubated for 30 min at room temperature and then dried under nitrogen at 90°C. Once dry, 80 l of a 10:1 mix (vol/vol) of n-butanol and acetyl chloride were added, and samples were heated at 90°C for 20 min followed by drying under nitrogen at 45°C. Next, an appropriate volume, usually between 50 and 100 l of 5% (vol/vol) N-heptafluorobutyrylimidazole in ethyl acetate, was added, and samples were left at room temperature for 15 min to form the N-butyl-heptaflurobutyrate derivative. This was necessary to enhance the peak areas for the small amount of homocysteine present in the tissue extracts but sufficiently mild to avoid chemical demethylation of methionine to homocysteine that was found to occur when the more common acylation reagent heptaflurobutyric anhydride was used, which yielded relatively large areas for homocysteine and at enrichments similar to the tissue methionine. Failure to recognize this problem during the pilot study meant that higher infusion rates of [1- 13 C]homocysteine were employed during experiment 2 than were necessary. Samples were then analyzed by GC-MS under negative chemical ionizationselective ion monitoring conditions with separation on a 30 m ϫ 0.25 mm ϫ 0.25 m ZB5-MS capillary column (Phenomenex, Macclesfield, Cheshire, UK). Fragment ions were measured at m/z 381, 382, 385, and 386 for methionine, 563, 564, and 567 for homocysteine (for concentration and enrichment), and 549 and 550 for cysteine (concentration only). For the model described below, it is essential that neither the dissection procedures nor the subsequent analytical techniques altered metabolite concentrations or enrichments. Therefore, for both experiments 1 and 2, appropriate tests were performed with fresh liver homogenates, including addition of various isotope mixtures, to ensure that the collection and processing procedures did not alter either the concentrations or isotopomer ratios of the various metabolites.
Mathematical Models of Whole Body and Tissue Metabolism for Methionine and Homocysteine
For the mathematical models, all enrichments are expressed as tracer-to-tracee ratios (TTR), where tracee includes naturally occurring 12 C and naturally occurring 13 C species. All flows and infusion rates are expressed in micromoles per hour. Rates of infusion of labeled methionine and homocysteine are designated as IM and IH, respectively. Methionine and homocysteine enrichments are denoted by EM and EH, respectively. Subscripts "p" and "t" refer to plasma and tissue, respectively. Subscripts 1, 4, and 5 refer to m ϩ 1, m ϩ 4, and m ϩ 5 molecules, respectively. The models are described first for the more complex isotope procedures used in experiment 2 (infusion of both labeled methionine and homocysteine), and then the simplified versions used for experiment 1 are detailed. The approaches adopted include allowance for the presence of labeled molecules in the infusates that are also formed by metabolism through the methionine cycle, e.g., the bis-[1-13 C,methyl-2 H3]methionine infused contained 5.3% [1- 13 C]methionine, the product of methylation of homocysteine synthesized from the bis-label.
For whole body calculations, the various irreversible loss rates (ILR) were calculated as ILR ϭ tracer infusion rate/E x where Ex is the TTR of the appropriate plasma metabolite (methionine or homocysteine). Minimum estimates of ILR were obtained when E x was in the same label form as the infusate (e.g., m ϩ 5 methionine or m ϩ 1 homocysteine in experiment 2 and m ϩ 4 methionine in experiment 1). Alternatively, labeled homocysteine generated within tissues and exported to plasma (m ϩ 1 for experiment 1 and m ϩ 4 for experiment 2) were used as surrogates for the TTR of intracellular methionine (38) , analogous to the use of keto-isocaproate for leucine kinetics (22) .
Let PS, PB, DM, OX, and ABS denote, at the whole body level, protein synthesis, protein breakdown, methionine demethylation, oxidation and absorption, respectively, while MH represents methylation of homocysteine. Then the inflows and outflows for tracee methionine are given by PB ϩ MH ϩ ABS ϭ PS ϩ DM and the inflow and outflows for tracee homocysteine correspond to DM ϭ MH ϩ OX then, for experiment 2:
This solves for PS ϩ DM. In addition: Fig. 2 was used. For intracellular methionine kinetics, the relative inflows from plasma methionine, intracellular homocysteine, and protein breakdown (enrichment assumed to be 0) can be determined by isotope dilutions. If the absolute rate of any of the three inflows is known, then rates can be calculated for the other two. For this model, it was assumed that protein degradation was the same as protein synthesis that was measured directly and expressed as micromoles per hour per gram, and this allowed inflows from plasma methionine and homocysteine to be estimated as the same units. Under steady-state conditions, the following equalities hold:
Mflux t ϭ Min t ϩ MH t ϩ PB t ϭ Mout t ϩ DM t ϩ PS t Hflux t ϭ Hin t ϩ DM t ϭ Hout t ϩ MH t ϩ OX t where Mfluxt and Hfluxt are the methionine and homocysteine fluxes through tissue t, Mint and Hint are methionine and homocysteine inward transport into tissue t, and Moutt and Houtt are methionine and homocysteine outward transport from tissue t.
For experiment 2, flows of m ϩ 5 methionine through tissue t are given by: EM 5p Min t ϭ EM 5t Mflux t
This gives Mint/Mfluxt. From the labeled methionine derived from the infusion of labeled homocysteine (experiment 2), it follows that EM 1p Min t ϩ EH 1t MH t ϭ EM 1t Mflux t (4) This then gives RMt/Mfluxt and PBt/MFluxt ϭ 1 Ϫ Mint/Mfluxt Ϫ MHt/Mfluxt. Based on protein synthesis measurements, and assuming that PS ϭ PB, Mfluxt and MHt can then be calculated.
PS was obtained as follows. First, the fractional rate of tissue protein synthesis (FSR; %/day) was calculated in experiment 2 from FSR ϭ TTR prot /TTR tf ϫ 1/day ϫ 100% where "prot" refers to protein-bound and "tf" to tissue free pool m ϩ 5 methionine TTR, and day is time of infusion in days. Second, these values were converted to micromoles per hour per gram tissue methionine used for protein synthesis by PS ϭ FSR/100 ϫ 1/24 ϫ C where C is concentration of protein-bond methionine ( There is no equivalent to Eq. 5 for experiment 1, i.e., DM/Hflux and Hin/Hflux cannot be calculated.
